company background image
6621

UniPharma TPEX:6621 Stock Report

Last Price

NT$11.25

Market Cap

NT$396.0m

7D

-1.7%

1Y

-15.1%

Updated

24 May, 2022

Data

Company Financials
6621 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

6621 Stock Overview

UniPharma Co., Ltd. engages in drug development activities.

UniPharma Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for UniPharma
Historical stock prices
Current Share PriceNT$11.25
52 Week HighNT$15.15
52 Week LowNT$10.80
Beta1.12
1 Month Change-6.64%
3 Month Change-6.64%
1 Year Change-15.09%
3 Year Change8.70%
5 Year Changen/a
Change since IPO-56.56%

Recent News & Updates

Shareholder Returns

6621TW PharmaceuticalsTW Market
7D-1.7%3.1%1.5%
1Y-15.1%2.8%-0.7%

Return vs Industry: 6621 underperformed the TW Pharmaceuticals industry which returned 2.8% over the past year.

Return vs Market: 6621 underperformed the TW Market which returned -0.7% over the past year.

Price Volatility

Is 6621's price volatile compared to industry and market?
6621 volatility
6621 Average Weekly Movement4.7%
Pharmaceuticals Industry Average Movement5.1%
Market Average Movement4.6%
10% most volatile stocks in TW Market8.2%
10% least volatile stocks in TW Market2.2%

Stable Share Price: 6621 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 6621's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199842Yu-Shan Wanghttps://www.uni-pharma.com

UniPharma Co., Ltd. engages in drug development activities. The company offers adhesion reduction and anesthesia solutions; and antidotes, as well as medical devices and in vitro-diagnostic products. IT also provides diagnostic tests in areas of oncology, gynecology, orthopedics, neurology, anesthesiology, and cardiology.

UniPharma Fundamentals Summary

How do UniPharma's earnings and revenue compare to its market cap?
6621 fundamental statistics
Market CapNT$396.01m
Earnings (TTM)-NT$74.41m
Revenue (TTM)NT$105.39m

3.8x

P/S Ratio

-5.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
6621 income statement (TTM)
RevenueNT$105.39m
Cost of RevenueNT$46.06m
Gross ProfitNT$59.33m
Other ExpensesNT$133.73m
Earnings-NT$74.41m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-2.11
Gross Margin56.29%
Net Profit Margin-70.60%
Debt/Equity Ratio0%

How did 6621 perform over the long term?

See historical performance and comparison

Valuation

Is UniPharma undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


1.33x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 6621's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6621's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: 6621 is unprofitable, so we can't compare its Price-To-Earnings Ratio to the TW Pharmaceuticals industry average.

PE vs Market: 6621 is unprofitable, so we can't compare its Price-To-Earnings Ratio to the TW market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6621's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 6621 is good value based on its Price-To-Book Ratio (1.3x) compared to the TW Pharmaceuticals industry average (2x).


Future Growth

How is UniPharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


52.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as UniPharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has UniPharma performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-52.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 6621 is currently unprofitable.

Growing Profit Margin: 6621 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 6621 is unprofitable, and losses have increased over the past 5 years at a rate of 52.9% per year.

Accelerating Growth: Unable to compare 6621's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6621 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2%).


Return on Equity

High ROE: 6621 has a negative Return on Equity (-25%), as it is currently unprofitable.


Financial Health

How is UniPharma's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 6621's short term assets (NT$261.4M) exceed its short term liabilities (NT$46.8M).

Long Term Liabilities: 6621's short term assets (NT$261.4M) exceed its long term liabilities (NT$3.8M).


Debt to Equity History and Analysis

Debt Level: 6621 is debt free.

Reducing Debt: 6621 has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6621 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 6621 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 12.9% each year


Dividend

What is UniPharma current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6621's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 6621's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6621's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6621's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 6621 has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Yu-Shan Wang

no data

Tenure

Yu-Shan Wang, Ph D., is General Manager of UniPharma Co., Ltd. Educations Doctor of Philosophy, Cancer Research Center, Department of Veterinary Medicine, National Taiwan University, Taipei, Taiwa...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

UniPharma Co., Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: UniPharma Co., Ltd.
  • Ticker: 6621
  • Exchange: TPEX
  • Founded: 1998
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: NT$396.011m
  • Shares outstanding: 35.20m
  • Website: https://www.uni-pharma.com

Number of Employees


Location

  • UniPharma Co., Ltd.
  • No.17, Lane 171
  • 3rd Floor
  • Taipei
  • 11494
  • Taiwan

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/24 00:00
End of Day Share Price2022/05/23 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.